Circulating lymphocytes continuously enter lymph nodes for immune surveillance through specialized blood vessels named high endothelial venules [1] [2] [3] [4] [5] , a process that increases markedly during immune responses. How high endothelial venules (HEVs) permit lymphocyte transmigration while maintaining vascular integrity is unknown. Here we report a role for the transmembrane O-glycoprotein podoplanin (PDPN, also known as gp38 and T1a) [6] [7] [8] in maintaining HEV barrier function. Mice with postnatal deletion of Pdpn lost HEV integrity and exhibited spontaneous bleeding in mucosal lymph nodes, and bleeding in the draining peripheral lymph nodes after immunization. Blocking lymphocyte homing rescued bleeding, indicating that PDPN is required to protect the barrier function of HEVs during lymphocyte trafficking. Further analyses demonstrated that PDPN expressed on fibroblastic reticular cells 7 , which surround HEVs, functions as an activating ligand for platelet C-type lectin-like receptor 2 (CLEC-2, also known as CLEC1B) 9, 10 . Mice lacking fibroblastic reticular cell PDPN or platelet CLEC-2 exhibited significantly reduced levels of VE-cadherin (also known as CDH5), which is essential for overall vascular integrity 11, 12 , on HEVs. Infusion of wild-type platelets restored HEV integrity in Clec-2-deficient mice. Activation of CLEC-2 induced release of sphingosine-1-phosphate 13, 14 from platelets, which promoted expression of VE-cadherin on HEVs ex vivo. Furthermore, draining peripheral lymph nodes of immunized mice lacking sphingosine-1-phosphate had impaired HEV integrity similar to Pdpn-and Clec-2-deficient mice. These data demonstrate that local sphingosine-1-phosphate release after PDPN-CLEC-2-mediated platelet activation is critical for HEV integrity during immune responses.
Lymph nodes (LNs) are essential sites for immune responses. They are organized into lobules, which are surrounded by lymphatic sinuses that deliver antigens from afferent lymphatic vessels to LNs for identification by naive lymphocytes that continually home through HEVs ( Supplementary Fig. 1 ). Lymphocyte trafficking is particularly prominent in mucosal LNs, as most foreign antigens enter the body through mucosal epithelium, and in draining peripheral LNs during immune responses 1, 15 . How HEVs accommodate a high rate of lymphocyte trafficking while maintaining their integrity remains unknown.
Platelets support vascular integrity in inflamed tissues by still undefined mechanisms 16 . Whether, and if so how, platelets protect HEV integrity in the LN is unexplored. PDPN, a ligand for the platelet activating receptor CLEC-2, is highly expressed in LNs. We developed mice with tamoxifeninducible global deletion of PDPN (Pdpn f/f ;CagCre, Supplementary  Fig. 2a-d) , and focused first on the mucosal LNs of mice around the weaning-age because development of adaptive immunity occurs early and primarily through mucosal LNs 17 . Tamoxifen administration from postnatal day 1 (P1) to P5 resulted in ,90% reduction of PDPN at P15 and complete loss at 1 month in both mucosal and peripheral LNs ( Supplementary Figs 2e and 3a, b, d ). Beginning at P15 and progressively worsening, Pdpn f/f ;CagCre pups exhibited massive bleeding primarily in mucosal LNs including mesenteric LNs (MLNs) and cervical LNs (CLNs), but rarely in peripheral (inguinal and popliteal) LNs (Fig. 1a, Supplementary Fig. 3 ). Histology and confocal imaging of MLNs revealed large numbers of extravasated red blood cells (RBCs) around HEVs but not non-HEV vessels of Pdpn f/f ;CagCre mice ( Fig. 1b-d) . Pdpn deletion starting at 3-4 weeks of age resulted in a similar mucosal LN bleeding phenotype, suggesting that PDPN is also important for LN vascular integrity in adults ( Supplementary Fig. 3c, d ).
In LNs, PDPN is expressed by endothelial cells of lymphatic vessels but not by blood vessels including HEVs ( Supplementary Fig. 4a ). However, PDPN is also highly expressed on fibroblastic reticular cells (FRCs), which surround HEVs and express ER-TR7, aSMA and PDGFRb 7, 18 (Supplementary Fig. 4b-d) . To address whether PDPN on FRCs is essential for LN vascular integrity, we generated Pdpn f/f ; PdgfrbCre mice, which lack PDPN in FRCs but otherwise exhibit normal FRC organization ( Supplementary Fig. 5b ;PdgfrbCre mice developed bleeding in mucosal LNs (Fig. 1e) . Pdpn f/f ;PdgfrbCre mice also had reduced levels of PDPN on lymphatic endothelial cells (LECs) in LNs ( Supplementary Fig. 5b-d) .
To rule out the contribution of endothelial PDPN to LN bleeding, we developed Pdpn f/f ;Tie2Cre mice, which lack PDPN specifically in LECs but not in FRCs ( Supplementary Fig. 6a-d) . Consistent with the previously described role of PDPN in the separation of blood and lymphatic vessels during embryonic development 8 , Pdpn f/f ;Tie2Cre mice exhibited blood-lymphatic vessel mixing phenotype (Supplementary Fig. 6e , data not shown). However, Pdpn f/f ;Tie2Cre mice did not exhibit bleeding around HEVs in the LN ( Supplementary Fig. 6e, f) . These results indicate that PDPN on FRCs rather than LECs prevents bleeding in LNs.
CLEC-2 is the only known receptor for PDPN 9, 10, 19 . To determine its importance for LN vascular integrity, we depleted CLEC-2 in wildtype neonates using a CLEC-2-specific monoclonal antibody, INU1 (ref. 19) . Administration of INU1 resulted in bleeding in mucosal LNs at P15 similar to Pdpn f/f ;CagCre mice (Fig. 1f, Supplementary Fig. 7a ). To determine the role of CLEC-2 in adult LNs, we made Clec-2 2/2 bone marrow chimaeras (Clec-2 2/2 BM chimaera, Supplementary Fig. 7b, c) , which, consistent with deleting Pdpn in adult mice, developed bleeding in mucosal LNs (Supplementary Fig. 7d ). CLEC-2 is primarily expressed on platelets 10, 19 ; however, it is also expressed on myeloid and dendritic cells. To verify whether CLEC-2 on platelets is required to protect LN vascular integrity, we developed mice lacking CLEC-2 specifically on platelets (Clec-2 f/f ;Pf4Cre, Supplementary Fig. 8a-c) .
;Pf4Cre mice developed spontaneous bleeding in mucosal LNs reminiscent of Pdpn-deficient mice (Fig. 1g, Supplementary Fig. 8d ). Collectively, these results indicate that FRC PDPN and platelet CLEC-2 are required to protect LN vascular integrity.
To explore where platelet CLEC-2 interacts with PDPN in the LN, we stained cryosections of LNs and found frequent associations of platelets with PDPN 1 FRCs at the abluminal sides of HEVs of wild-type but not Pdpn-deficient mice (Fig. 2a, Supplementary Fig. 9 ). Furthermore, intravenously transfused, fluorescently labelled CLEC-2-expressing wild-type platelets were detected on the abluminal sides of HEVs in close association with PDPN 1 FRCs of Clec-2 2/2 BM chimaeras (Fig. 2b) , supporting the hypothesis that platelets interact with FRCs around HEVs in a PDPN-CLEC-2-dependent manner.
Mucosal LNs but not peripheral LNs of Pdpn-or Clec-2-deficient mice exhibit spontaneous bleeding, suggesting phenotypic differences between these two types of LNs. We found that mucosal LNs were significantly more permeable to Evans blue dye than peripheral LNs in the steady-state (Fig. 2c) . We noted that mucosal but not peripheral HEVs express MAdCAM-1 ( Supplementary Fig. 10a, b) . However, after an immune challenge (ovalbumin/complete Freund's adjuvant, OVA/CFA), HEVs in peripheral LNs of wild-type mice had increased MAdCAM-1 expression and permeability, resembling mucosal HEVs ( Supplementary Fig. 10b , data not shown). Importantly, Pdpn f/f ;CagCre or Clec-2 f/f ;Pf4Cre but not wild-type mice developed bleeding in draining peripheral LNs after OVA/CFA challenge (Fig. 2d) . These results suggest a crucial role for PDPN-CLEC-2 interactions in maintaining vascular integrity of steady-state mucosal and immunized peripheral LNs, which share a similar 'reactive' functional and molecular phenotype and are specifically vulnerable to bleeding. Consistent with this, bleeding was observed in mucosal LNs of 3-week-old Pdpn f/f ;PdgfrbCre mice, but not Pdpn f/f ;PdgfrbCre mice bred into a Rag1 2/2 background that lacks lymphocytes (Fig. 2e) . In addition, depleting CLEC-2 with INU1 resulted in mucosal LN bleeding in 2-week-old wild-type but not Rag1 2/2 mice, highlighting the importance of lymphocytes in promoting mucosal LN bleeding (Supplementary Fig. 11a ). We next administered a monoclonal antibody to L-selectin (Mel-14) that blocks lymphocyte trafficking through HEVs ( Supplementary Fig. 11b ) 20 . Mel-14 treatment considerably reduced the bleeding observed in the draining peripheral LN of immunized Pdpn f/f ;CagCre mice compared with an isotype control (Fig. 2f, Supplementary Fig. 11c ). A previous study shows that activated platelets facilitate lymphocyte adhesion to HEVs 21 . However, whether platelets transmigrate with or following lymphocytes to the abluminal space of HEVs to fulfil additional function is unknown. We found that draining peripheral LNs from immunized wild-type mice had a significant increase in the number of platelets at the abluminal sides of HEVs, which was abolished after Mel-14 treatment, demonstrating that platelets migrate across HEVs in a lymphocyte transmigrationdependent manner to interact with FRCs ( Supplementary Fig. 11d ). These data support the model that interactions between platelets and FRCs are critical for preventing bleeding in 'reactive' LNs during immune responses when lymphocyte trafficking is increased.
To determine whether impaired HEV barrier function is responsible for the observed LN bleeding when PDPN is absent, we intravenously injected fluorescein isothiocyanate (FITC)-conjugated dextran immediately before euthanasia. FITC-dextran was contained within HEVs of wild-type MLNs. However, FITC-dextran leaked from HEVs, but not from non-HEV blood vessels in LNs and other organs, of Pdpn f/f ; CagCre mice (Fig. 3a, Supplementary Fig. 12a and data not shown). Furthermore, intravenously injected, fluorescently labelled RBCs were detected outside of HEVs in Pdpn f/f ;CagCre but not in wild-type mice (Fig. 3b) . Ultrastructural analyses indicated that abnormal gaps between endothelial cell membranes were specific to HEVs of Pdpn f/f ;CagCre mice, and RBCs were frequently observed between or outside of high endothelial cells in Pdpn f/f ;CagCre mice (Fig. 3c, Supplementary Fig. 12b ). Together, these data indicate that, in the absence of PDPN, impaired vascular barrier function and defective junctions are restricted to HEVs.
VE-cadherin (VE-cad) is an integral component of endothelial adherens junctions and barrier function 22 . We found that levels of VE-cad were reduced in HEVs of Pdpn f/f ;CagCre MLNs starting at P8, before the onset of bleeding (Fig. 3d, Supplementary Fig. 12c, d) , consistent with the idea that loss of HEV junctional integrity contributes to the onset of bleeding. Furthermore, following the loss of PDPN, b-catenin, another component of endothelial adherens junctions 22 , was decreased Insets show VE-cad staining in non-HEV blood vessels. e, Confocal analysis of intravenously injected FITC-dextran in MLNs from wild-type or Clec2 2/2 BM chimaeras with or without previous transfusions of wild-type platelets. Arrows indicate vascular leak of FITC-dextran. Inset depicts non-HEV blood vessels. Graphs on the right quantify number of leaking vessels (mean 6 s.d., 300 vessels per group, n 5 3). f, Anti-VE-cad staining of HEVs and non-HEV blood vessels in wild-type BM chimaeras, and Clec2 2/2 BM chimaeras without or with previous transfusions with wild-type platelets. Dagger indicates nonspecific staining as also observed in isotype controls. Graphs on the right quantify VE-cad staining (mean 6 s.d., 300 vessels per group, n 5 3). Tissues were from 1-month-old (a-c) or 12-week post-BM transplantation (e, f) mice unless otherwise specified. Dashed lines mark HEVs. Data represent at least three individual experiments. Scale bars, 2 mm (transmission electron microscopy), 50 mm (confocal images (inset a, b and d, 25 mm) ). ***P , 0.001. Fig. 12e ) and expression of N-cadherin, which is essential for endothelial-stromal cell junctions 22 , was reduced around HEVs ( Supplementary Fig. 12f ). Further analyses indicate that VE-cad was expressed at higher levels in peripheral HEVs than in mucosal HEVs of wild-type mice ( Supplementary Fig. 13a ). ZO-1 (also known as TJP1) 22 , another junction molecule, was detected on peripheral but not mucosal HEVs. However, HEVs in draining peripheral LNs of immunized wild-type mice exhibited reduced VE-cad and ZO-1 expression, resembling MLNs of wild-type mice ( Supplementary Fig. 13a, b) . Consistent with the bleeding in draining peripheral LNs of immunized Pdpn-or Clec-2-deficient mice (Fig. 2d) , these LNs exhibited a further reduction of VE-cad on their HEVs (Supplementary Fig. 13a ), which was normalized by blocking lymphocyte trafficking with Mel-14 ( Supplementary Fig. 13c ). Furthermore, blocking VE-cad increased permeability in draining peripheral LNs of immunized wild-type mice ( Supplementary Fig. 14) . These results support the idea that interactions of PDPN and CLEC-2 preserve HEV barrier function primarily by promoting VE-cad expression on HEVs.
HEVs of Clec-2
BM chimaeras exhibited increased permeability to intravenously injected FITC-dextran (Fig. 3e) . To test whether this phenotype could be rescued by wild-type platelets, Clec-2 2/2 BM chimaeras were transfused daily with wild-type platelets for 4 days before euthanasia. HEVs of Clec-2 2/2 BM chimaeras that received wild-type platelets exhibited significantly decreased permeability to FITC-dextran compared to controls (Fig. 3e) . Notably, wild-type and Clec-2 2/2 BM chimaeras transfused with wild-type platelets expressed comparable levels of VE-cad on HEVs (Fig. 3f, Supplementary Fig. 15 ). Together, these results demonstrate that PDPN and platelet CLEC-2 are essential for preserving adherens junctions of HEVs.
Platelet aggregation is essential for haemostasis 16, 23 . However, blocking aggregation with a monoclonal antibody to integrin aIIbb3 did not increase permeability in draining peripheral LNs of immunized wildtype mice (Supplementary Fig. 14) . This suggests that a platelet function mediated by PDPN-CLEC-2 apart from aggregation is required for HEV integrity. Sphingosine-1-phosphate (S1P) 13, 14 , a bioactive lipid, is a strong candidate for mediating this platelet function as it is known to regulate vascular integrity through interactions with its G-proteincoupled receptors on endothelial cells 13 . Although platelets generate and store S1P 24 , whether PDPN-CLEC-2-mediated platelet activation causes S1P release is unknown. To test this, we stimulated wild-type and Clec-2 2/2 platelets with the monoclonal antibody INU1, which activates CLEC-2 signalling in vitro 19 , and observed a CLEC-2-dependent S1P release from platelets (Fig. 4a) . Furthermore, PDPN 1 but not PDPN 2 melanoma cells induced the release of S1P from wild-type but not Clec-2 2/2 platelets (Supplementary Fig. 16a, b) , indicating that interactions between PDPN and CLEC-2 induce S1P release from platelets. Next, we found that MLN slices cultured ex vivo with fetal bovine serum (FBS), but not lipiddepleted FBS, retained VE-cad expression on their HEVs (Fig. 4b,  Supplementary Fig. 16c ), supporting the idea that lipids, such as S1P, maintain HEV adherens junctions. The addition of wild-type but not Clec-2 2/2 platelets rescued VE-cad levels on HEVs of MLN slices cultured in lipid-depleted FBS-containing media. Wild-type platelets were unable to restore HEV VE-cad expression on MLN slices from Pdpn-deficient mice (Fig. 4b, Supplementary Fig. 16c ), demonstrating that FRC PDPN and platelet CLEC-2 are required for normal VE-cad expression on HEVs. The increase of VE-cad on HEVs in the presence of wild-type platelets is due, at least in part, to the activation of the S1P 
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receptor 1 (S1PR1), because the S1PR1 antagonist, W146 (ref. 14) , blocked the wild-type platelet-induced VE-cad expression on HEVs (Fig. 4b, Supplementary Fig. 16c ). Furthermore, platelets from S1P-deficient (referred to here as S1P less ) mice 13 , did not rescue VE-cad expression on HEVs of MLNs (Fig. 4b, Supplementary Fig. 16c ), supporting the importance of platelet S1P. S1P less mice did not develop spontaneous mucosal LN bleeding, probably due to reduced lymphocyte transmigration through HEVs because of lower circulating lymphocytes 25 ( Supplementary Fig. 17a ). However, after OVA/CFA challenge of the hindlimb, the draining peripheral LNs of S1P less mice exhibited bleeding, increased permeability to FITC-dextran, and decreased VE-cad expression on HEVs, resembling mice lacking PDPN or CLEC-2 (Fig. 4c, d, Supplementary Fig. 17b-d) . A daily transfusion for four consecutive days of wild-type but not Clec-2 2/2 platelets resulted in higher levels of VE-cad on HEVs and reduced vascular leak of injected FITC-dextran from HEVs of draining peripheral LNs of immunized S1P less mice (Fig. 4d, Supplementary Fig. 18 ). Taken together, these data indicate that PDPN-CLEC-2-dependent local release of S1P from platelets plays a critical role in maintaining HEV integrity during immune responses.
Unlike other venules, HEVs are not circumscribed by typical pericytes and collagen-containing matrix that would activate platelets. Instead, they are surrounded by a perivenular sleeve of FRCs that sequester collagen fibres 26, 27 . Our findings reveal an important new role for FRC PDPN, which is well positioned to interact with CLEC-2 on extravasated platelets (Fig. 4e) . S1P in the blood is known to regulate vascular integrity 13 . Our data demonstrate that PDPN-CLEC-2-dependent platelet activation causes release of S1P in the perivenular space that preserves VE-cad expression on HEVs (Fig. 4e) . Thus, cross-talk between FRCs, platelets and HEVs is essential to maintain HEV integrity in situations of increased lymphocyte trafficking such as chronic inflammation. Recently, components of the CLEC-2 signalling pathway have been implicated in preventing inflammation-induced haemorrhage in the skin and lung 28 . Therefore, PDPN-CLEC-2-mediated local S1P release from platelets may protect vascular integrity in other inflamed tissues.
METHODS SUMMARY
Mice were maintained in specific-pathogen-free facilities and used under protocols approved by the IACUC of the Oklahoma Medical Research Foundation. For all experiments, a minimum of six mutants of each line and littermates were examined unless otherwise stated based on the highly penetrant phenotypes observed in our preliminary studies. Data are expressed as mean 6 s.d. and represent at least three experiments unless otherwise specified. Statistical analysis was performed with Student's t-tests and differences were considered significant when P , 0.05. Generation of novel mouse lines, bone marrow transplantation, depletion of CLEC-2, platelet transfusion, immune challenge, L-selectin blocking, permeability assays, platelet and RBC labelling/transfusions, immunofluorescence imaging, flow cytometry, electron microscopy, S1P concentration analysis and ex vivo LN slice experiments are described in detail in the Methods. ), and the neomycin resistance selection cassette (Neo) was flanked by Frt sites (Supplementary Fig. 2a) . The NotI-linearized construct was electroporated into C57BL/6-derived embryonic stem (ES) cells, and correctly targeted clones were identified by Southern blots. The Frt-flanked Neo was removed by transient expression of Flp recombinase in the positive ES clones to avoid potential undesirable effects of the Neo cassette. ES cells with normal karyotype bearing a floxed Pdpn allele were microinjected into B6/Tyr blastocytes, which were subsequently implanted into pseudopregnant foster mothers. Male chimaeras were bred with C57BL/6J females for germline transmission. Heterozygous mice were then crossed to generate Pdpn f/f mice ( Supplementary Fig. 2a, b) . ;Tie2Cre) were generated by crossing Pdpn f/f mice with PdgfrbCre Tg mice (Tg(Pdgfrb-cre)9Rha) 30 or Tie2Cre Tg mice (Tg(Tek-cre)1Ywa) 31 , respectively.
Conditional Clec-2 knockout mice were generated in which exons 3 and 4 of the Clec-2 allele are flanked by loxP sites (Clec-2 f/f ). Deletion of exons 3 and 4 induces a premature stop codon that blocks the expression of the extracellular domain of CLEC-2 ( Supplementary Fig. 8a ). ES clones with correct homologous recombination were microinjected into B6 blastocytes, which were subsequently implanted into pseudopregnant foster mothers. Male chimaeras were bred with ACTB-FLP1 females (B6.Cg-Tg(ACTFLPe)9205Dym/J, Jackson Laboratory) for germline transmission and removal of the Neo cassette. Heterozygous mice were then crossed to generate Clec-2 f/f mice. Clec-2 f/f mice were crossed with Pf4Cre Tg mice (C57BL/6-Tg(Pf4-cre)Q3Rsko/J, Jackson Laboratory) to generate mice deficient for Clec-2 on platelets (Clec-2
(Jackson Laboratories) 32 and S1P less mice 13 were previously described.
Mice were housed in specific pathogen-free barrier facilities. All mice were of mixed genetic background (129S and C57BL/6J) unless otherwise stated. Sex-and age-matched wild-type littermate controls were used for all experiments. Mice were included in studies if they exhibited deletion efficiency of more than 75% for the Pdpn deficiency and 95% for the Clec-2 deficiency. Random assignment to treatment groups was used in antibody blocking and platelet transfusion studies in vivo. No blinding was used in this study. Animal studies were approved by the Institutional Animal Care and Use Committee of the Oklahoma Medical Research Foundation. Microscopy. Organs were photographed at autopsy. For histology, samples were fixed in 4% paraformaldehyde (PFA) overnight at 4 uC, washed and embedded in paraffin. Sections (5 mm) were stained with haematoxylin and eosin. Confocal microscopy was performed as previously described 8 . Briefly, tissues were fixed in 4% PFA overnight at 4 uC, washed in PBS, cryoprotected in 20% sucrose in PBS at 4 uC overnight, embedded in 50% tissue freezing medium/50% OCT and cryosectioned (20-30-mm) . Sections were blocked for 1 h at room temperature and incubated with primary antibodies overnight at 4 uC. Secondary antibodies were added for 1 h at room temperature. Primary antibodies were to murine thrombocytes (Accurate Chemical & Scientific Corporation), PDPN (clone 8. ImmunoResearch) . Alternatively, Cy3-conjugated anti-aSMA (clone 1A4, Sigma-Aldrich) was also used. Images were collected using an Olympus IX81 with DSU spinning-disk confocal microscope and a Hamamatsu ORCA-R 2 camera. Images were analysed using Slidebook 5.0 (Intelligent Imaging Innovations). Immunoblotting. As previously described 8 , tissues were collected, homogenized and total protein concentration was calculated using a spectrophotometer (Eppendorf). Tissue lysates containing 20 mg total protein were resolved on a 10% SDS-PAGE resolving gel and transferred to an Immobilon-P membrane (EMD Millipore).
Membranes were probed with a Syrian hamster anti- mouse PDPN (clone 8.1.1) , rat anti-mouse VE-cad (clone BV13, Abcam), or mouse anti-GAPDH monoclonal antibodies. Membranes were washed and probed with horseradish peroxidaseconjugated secondary antibodies. Signal was developed using ECL reagents (Thermo Scientific). Bone marrow chimaeras. Bone marrow cells from both femurs and tibias were collected from wild-type and a limited number of Clec-2 2/2 mice that survived after weaning in our facility by flushing the marrow cavity with 5 ml of HBSS containing 1 mM EDTA, as previously described 8 . The cell suspension was then run through a 100 mm mesh cell strainer to remove aggregates, centrifuged at 300g for 8 min and resuspended in sterile saline. Cells (5 3 10 6 ) in 200 ml saline were injected retroorbitally into wild-type recipient mice that had been irradiated with 1100 rad. Engraftment efficiency was determined using flow cytometry analysis on a FACSCalibur INU1) 19 at P1, P6 and P11. These mice were then killed on P15. Labelling of erythrocytes or platelets. For erythrocyte labelling, whole blood from wild-type mice was collected into EDTA-coated Microvette 500 K3E tubes (Sarstedt), washed in HBSS (without Ca 21 and Mg
21
) and centrifuged at 1200g for 10 min. Cells were resuspended in HBSS (without Ca 21 and Mg
) at a 1:5 dilution of the original volume and incubated with 5 mM CM-DiI (Invitrogen). Washed, labelled RBCs were resuspended at a 75% haematocrit and 200 ml were intravenously injected into mice. For platelet labelling, platelet-rich plasma was obtained by collecting whole blood into an Eppendorf tube containing 20 IU heparin, adding 500 ml modified Tyrode's buffer (137 mM NaCl, 0.3 mm Na 2 HPO 4 , 2 mM KCl, 12 mM NaHCO 3 , 5 mM HEPES, 5 mM glucose, pH 7.3) containing 0.35% BSA and centrifuged for 8 min at 100g at room temperature. Platelets were collected by centrifuging for 10 min at 1000g. Washed platelets were incubated with 5 mM CellTracker Green (Invitrogen) for 30 min at 37 uC. Labelled platelets were washed in HBSS (without Ca 21 and Mg 21 ) and resuspended in HBSS (without Ca 21 and Mg 21 ) before intravenous injection. Efficiency of labelling was confirmed using a FACSCalibur (Becton Dickinson) and analysed using CellQuest Pro (Becton Dickinson). Vascular permeability analysis. To determine the vascular permeability in MLNs, 250 mg of lysine-fixable FITC-dextran (2,000 kDa, Invitrogen) in 40 ml total volume physiologic saline was injected immediately before killing animals. Frozen sections of MLNs were stained with anti-CD31 or PNAd antibodies and analysed for the presence of dextran outside the blood vessels. Alternatively, 500 mg of lysine-fixable FITC-dextran (2,000 kDa, Invitrogen) or fluorescently labelled RBCs resuspended at a 75% haematocrit were intravenously injected into mice 1 min or 10 min, respectively, before the mice were killed. Frozen sections of LN were stained with an anti-CD31 antibody and analysed for the presence of fluorescently labelled RBCs outside the blood vessels. Evans blue dye (2% in saline) was intravenously injected 5 min before killing the mice. Mice were perfused with heparanized saline and LNs were placed in formamide (Fisher Scientific) overnight at 55 uC. Tissues were removed from formamide and absorbance was measured at 620 nm in a spectrophotometer 33 . Transmission electron microscopy (TEM). LNs were removed and fixed overnight at 4 uC in 2% gluteraldehyde in 0.1 M cacodylate buffer (pH 7.3). Tissues were washed in 0.1 M cacodylate buffer and post-fixed in 1% osmium tetroxide (1.5 h) and 1% tannic acid (1 h). Tissues were dehydrated through graded alcohols and embedded in EPON resin (EMS). Semi-thin sections (,300-nm) were cut using an ultramicrotome (RMC 7000, RMC) equipped with a diamond knife and stained with toluidine blue, some of which were imaged. Ultrathin sections (,70-nm) were stained with uranyl acetate and lead citrate and visualized using a
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Hitachi H-7600 electron microscope with a 4 megapixel digital monochrome camera and AMT-EM image acquisition software (Advanced Microscopy Techniques). Platelet transfusion experiments. Platelets were isolated as described above and were intravenously injected into Clec-2 34 . Control lateral hindlimbs were injected with an equivalent volume of saline as a control. Mice were killed 1 week after challenge and popliteal LNs were processed for immunofluorescence staining. L-selectin blockade and in vitro leukocyte rolling assay. Three-to four-week-old mice were challenged with 250 mg OVA/CFA into the hindlimb. Mice were then administered i.p. 30 mg of an anti-mouse L-selectin antibody 20 every other day for 1 week. Mice were killed and popliteal LNs were dissected and analysed.
To determine the blocking efficiency of Mel-14, an in vitro lymphocyte rolling assay was used. Briefly, 100 mg ml 21 streptavidin was coated on 35-mm polystyrene dishes overnight at 4 uC. After washing three times with HBSS, the dishes were blocked with 1% human serum albumin in HBSS for 2 h at 4 uC and then incubated with biotin conjugated 6-sulfo-sLe x , a ligand for L-selectin, for 2 h at 4 uC
35
. Isolation of peripheral leukocytes was described previously 36 . Heparinized blood was obtained from wild-type or Pdpn f/f ;CagCre mice that were treated with Mel-14 or rat IgG. After lysis of red blood cells, leukocytes were centrifuged at 100g for 10 min. Leukocytes (0.1 3 10 6 per ml) were perfused over 6-sulfo-sLe x coated surface under shear stress at 1.0 dyn per cm 2 . The number of rolling cells was counted using the Element software (Nikon). In vivo blockade of VE-cad and integrin aIIbbIIIa. After hindlimb challenge with OVA/CFA, mice were i.p. injected with 30 mg every other day of a monoclonal antibody against VE-cad (clone 11D4.1, BD Pharmingen) or against activated integrin aIIbbIIIa (clone JON/A) 37 . One week after immune challenge, Evans blue dye permeability assays were performed as described above. Peripheral lymphocyte counts. For measuring peripheral lymphocyte counts, whole blood obtained in EDTA-coated tubes was used to obtain a complete blood count using a Hemavet.
Development of PDPN
1 and PDPN 2 cell line. Parental murine melanoma cell line B16-F0, which contains PDPN 1 and PDPN 2 cells, was purchased from American Type Culture Collection (ATCC). Cells were cultured in DMEM containing 10% heat-inactivated FBS and 1% L-glutamine/penicillin/streptomycin (Cellgro) at 37uC in a humidified atmosphere of 5% CO 2 . B16-F0 cells were stained with anti-murine PDPN monoclonal antibody (clone 8.1.1) and a DyLight488-conjugated secondary antibody. Stained cells were then sorted with a FACSAria III cell sorter (BD Biosciences) to generate the PDPN 1 and PDPN 2 B16-F0 melanoma cells. Analysis of S1P concentration. Platelets were isolated from wild-type or Clec-2-deficient mice as before. After being washed with modified Tyrode's buffer containing 0.35% fatty acid-free BSA (Sigma-Aldrich), platelets (1 3 10 8 in 100 ml) were then incubated with a monoclonal antibody against CLEC-2 (clone INU1 at 10 mg ml 21 ) for 10 min at room temperature. The supernatant was collected and S1P concentration was determined using an S1P ELISA kit (Echelon Biosciences) according to the manufacturer's protocol. Alternatively, platelets were incubated with 5 3 10 5 PDPN 1 or PDPN 2 cells for 10 min at room temperature. Then the supernatant was collected and S1P concentration was quantitated by electrospray ionisation tandem mass spectrometry (ESI-MS/MS) using stable isotope dilution with heptadeuterated S1P (Avanti Polar Lipids) as the internal standard as described previously 38 . Ex vivo LN slice culture. MLNs were dissected from wild-type and Pdpn-deficient mice and embedded in low melting point agarose (Invitrogen) at 37uC. Blocks were cooled on ice and sectioned (,250 mm) using a Vibratome (McIlwain tissue chopper). LN slices were then co-incubated with washed platelets (2 3 10 7 in 100 ml of DMEM containing 10% charcoal stripped FBS; Invitrogen), isolated from wild-type, Clec-2 2/2 , or S1P less mice, for 1.5 h at 37 uC with gentle shaking. In some experiments, normal FBS or the S1PR1 antagonist, W146 (5 mM, Cayman Chemical), was included. MLN slices were then fixed in 4% PFA in PBS for 30 min and processed for cryopreservation. Cryosections were stained with antibodies against CD31 (clone 2H8, Abcam) and VE-cad (clone 11D4.1, BD Pharmingen). Quantification of Pdpn deletion, dextran leakage or VE-cad intensity. PDPN levels were calculated using ImageJ software to compare the mean intensities between the groups from a minimum of 5 low magnification (310) images. For quantification of FITC-dextran leakage, six cryosections were cut per mouse and each section was analysed for the total number of HEVs (,50 per section of MLNs) and non-HEVs based on CD31 or PNAd staining and morphology. The number of vessels that exhibited dextran outside the vessel was determined and the percentage of 'leaky' vessels compared to the total number of that vessel type was determined. Similarly, the percentage of VE-cad expression on vessels from MLN cryosections was determined by comparing the number of HEV and non-HEV that were VE-cad positive to the total number of vessel type. Alternatively, VE-cad intensities on HEVs were determined using ImageJ analysis software. Statistical analysis. Statistical tests were performed using Prism software (GraphPad). Two-sided, Student's t-tests were performed after the data were confirmed to fulfil the criteria of normal distribution and equal variance. Differences were considered statistically significant when P , 0.05.
